SCM
CMMB

Stonepine Capital Management’s Chemomab Therapeutics CMMB Stock Holding History

Stonepine Capital Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$78.9K – 72
2025
Q3 		$78.9K Buy
+30,000
New +$111K 0.06% 56

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stonepine Capital Management's CMMB Position: Q4 2025 in Review

Stonepine Capital Management sold out of Chemomab Therapeutics (CMMB) in Q4 2025, closing a stake of 30,000 shares — an estimated $78.9K sold.

Stonepine Capital Management first reported a position in CMMB in Q3 2025 and held it in 1 quarter. The position peaked at $78.9K in Q3 2025. 14 funds tracked by Wall St. Rank hold CMMB as of Q4 2025.

  • Stonepine Capital Management reported no remaining Chemomab Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 30,000 Chemomab Therapeutics shares in Q4 2025, an estimated $78.9K.
  • Stonepine Capital Management first reported a position in Chemomab Therapeutics in Q3 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Chemomab Therapeutics position peaked at $78.9K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.